HK1190153A1 - 用於治療心血管和血液病的取代的二氫吡唑啉酮 - Google Patents

用於治療心血管和血液病的取代的二氫吡唑啉酮

Info

Publication number
HK1190153A1
HK1190153A1 HK14103324.5A HK14103324A HK1190153A1 HK 1190153 A1 HK1190153 A1 HK 1190153A1 HK 14103324 A HK14103324 A HK 14103324A HK 1190153 A1 HK1190153 A1 HK 1190153A1
Authority
HK
Hong Kong
Prior art keywords
treating cardiovascular
hematological diseases
dihydropyrazolones
substituted
substituted dihydropyrazolones
Prior art date
Application number
HK14103324.5A
Other languages
English (en)
Inventor
Kai Thede
Ingo Flamme
Felix Oehme
Jens-Kerim Ergden
Friederike Stoll
Joachim Schuhmacher
Hanno Wild
Peter Kolkhof
Hartmut Beck
Jrg Keldenich
Metin Akbaba
Mario Jeske
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of HK1190153A1 publication Critical patent/HK1190153A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
HK14103324.5A 2006-10-26 2014-04-08 用於治療心血管和血液病的取代的二氫吡唑啉酮 HK1190153A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006050516A DE102006050516A1 (de) 2006-10-26 2006-10-26 Substituierte Dihydropyrazolone und ihre Verwendung

Publications (1)

Publication Number Publication Date
HK1190153A1 true HK1190153A1 (zh) 2014-06-27

Family

ID=38734870

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10106809.6A HK1140478A1 (en) 2006-10-26 2010-07-13 Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
HK14103324.5A HK1190153A1 (zh) 2006-10-26 2014-04-08 用於治療心血管和血液病的取代的二氫吡唑啉酮

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10106809.6A HK1140478A1 (en) 2006-10-26 2010-07-13 Substituted dihydropyrazolones for treating cardiovascular and haematological diseases

Country Status (41)

Country Link
US (5) US8389520B2 (zh)
EP (3) EP2383269B1 (zh)
JP (2) JP5247712B2 (zh)
KR (1) KR101455879B1 (zh)
CN (2) CN101631785B (zh)
AR (1) AR063392A1 (zh)
AU (1) AU2007328052B2 (zh)
BR (1) BRPI0717367B8 (zh)
CA (1) CA2667382C (zh)
CO (1) CO6170359A2 (zh)
CR (2) CR10750A (zh)
CU (2) CU23743B7 (zh)
CY (1) CY1114272T1 (zh)
DE (1) DE102006050516A1 (zh)
DK (2) DK2084151T3 (zh)
ES (3) ES2421454T3 (zh)
GT (1) GT200900095A (zh)
HK (2) HK1140478A1 (zh)
HN (1) HN2009000784A (zh)
HR (2) HRP20130779T1 (zh)
IL (2) IL198289A (zh)
MA (1) MA30914B1 (zh)
MX (1) MX2009004324A (zh)
MY (1) MY169564A (zh)
NO (1) NO343308B1 (zh)
NZ (2) NZ596583A (zh)
PE (3) PE20120635A1 (zh)
PH (1) PH12013500578A1 (zh)
PL (2) PL2084151T3 (zh)
PT (2) PT2084151E (zh)
RS (1) RS52924B (zh)
RU (2) RU2469031C2 (zh)
SG (1) SG176421A1 (zh)
SI (1) SI2084151T1 (zh)
SV (1) SV2009003236A (zh)
TN (1) TN2009000132A1 (zh)
TW (3) TWI437991B (zh)
UA (1) UA98125C2 (zh)
UY (1) UY30663A1 (zh)
WO (1) WO2008067871A1 (zh)
ZA (1) ZA200902705B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
PT2382205E (pt) * 2008-12-29 2014-07-28 Sanofi Sa Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, sua preparação e sua aplicação terapêutica como activadores de hif
ES2511917T3 (es) 2008-12-29 2014-10-23 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y su aplicación en terapéutica
FR2949466A1 (fr) * 2009-08-28 2011-03-04 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
FR2940651B1 (fr) * 2008-12-29 2013-05-03 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
IT1393337B1 (it) 2009-03-06 2012-04-20 Italiana Sint Spa Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP3461820B1 (en) 2011-10-25 2020-07-29 Janssen Pharmaceutica NV Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
EP2628722A1 (en) * 2012-02-16 2013-08-21 Bayer CropScience AG CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles
KR20140138208A (ko) 2012-03-30 2014-12-03 다이이찌 산쿄 가부시키가이샤 4-알카노일아미노-3-피라졸론 유도체
MY184577A (en) * 2012-05-08 2021-04-06 Bayer Pharma AG Method for the preparation of triazole compounds
CA2873674A1 (en) 2012-05-29 2013-12-05 Momentive Performance Materials Gmbh Preparation of isocyanato silanes
SG11201506749XA (en) 2013-03-29 2015-09-29 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
MX2016004628A (es) 2013-10-17 2016-08-01 Bayer Pharma AG Formas de dosificacion farmaceutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h- pirazol-5-olato de sodio.
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
CN107778262A (zh) * 2016-08-24 2018-03-09 尹玉新 1,5‑双取代四氮唑类化合物及其制备方法和应用
CN109694380B (zh) * 2017-10-23 2022-09-27 中国医药研究开发中心有限公司 二氢吡唑啉酮类化合物及其制备方法和医药用途
CN111825690B (zh) * 2019-04-17 2022-09-27 中国医药研究开发中心有限公司 一种phd抑制剂的新晶型及其制备方法
US11579118B2 (en) 2019-06-03 2023-02-14 Tdw Delaware, Inc. Single point contact triaxial sensor head for an inline inspection tool
US10702525B1 (en) 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents
WO2021163727A1 (en) * 2020-02-11 2021-08-19 AcuraStem Incorporated Pikfyve kinase inhibitors
CN115551839A (zh) 2020-02-18 2022-12-30 拜耳公司 作为农药的杂芳基-三唑化合物
AR121626A1 (es) * 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso
EP3888684A1 (en) 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE424016C (de) 1923-05-20 1926-01-14 Allg Vergasungs Ges M B H Fa Schachtofen mit Schwelaufsatz zur Vergasung und Verschwelung bituminoeser Stoffe
FR1519069A (fr) 1966-04-13 1968-03-29 Geigy Ag J R Dérivés du sulfanilamide et leur préparation
US4075003A (en) 1975-12-11 1978-02-21 Eli Lilly And Company Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones
GR63123B (en) 1975-12-11 1979-09-11 Lilly Co Eli Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones
PL103509B1 (pl) 1976-09-20 1979-06-30 Lilly Co Eli Srodek chwastobojczy
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
DE3527157A1 (de) 1985-07-30 1987-02-12 Bayer Ag 1-heteroaryl-4-aryl-pyrazol-derivate
DE4204919A1 (de) 1992-02-19 1993-08-26 Bayer Ag Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen
DE4240168A1 (de) 1992-11-30 1994-06-01 Bayer Ag Cumarin-Derivate, Verfahren zu ihrer Herstellung und ihrer Verwendung
FR2725988B1 (fr) 1994-10-24 1997-01-24 Roussel Uclaf Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH10306077A (ja) * 1997-05-07 1998-11-17 Daiichi Rajio Isotope Kenkyusho:Kk ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬
DE19909237A1 (de) 1999-03-03 2000-09-07 Merck Patent Gmbh Pyrazol-3-on-derivate
US6887872B2 (en) * 2000-03-20 2005-05-03 N-Gene Research Laboratiories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
US7569592B2 (en) 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2522441A1 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
CA2520870A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004236690A1 (en) 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
CA2530679A1 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
AT7634U1 (de) 2004-06-29 2005-06-27 Binder Co Ag Detektiervorrichtung und sortiervorrichtung
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
MX2007011280A (es) 2005-03-16 2007-11-15 Aventis Pharma Inc Dipirazoles como farmacos del sistema nervioso central.
EP1881979B1 (en) * 2005-04-26 2010-08-11 NeuroSearch A/S Novel oxadiazole derivatives and their medical use
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
DE102010044131A1 (de) 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
UA98125C2 (ru) 2012-04-25
US20140031329A1 (en) 2014-01-30
PE20120635A1 (es) 2012-05-20
IL198289A (en) 2015-03-31
EP2084151B1 (de) 2013-05-29
SV2009003236A (es) 2010-01-19
TWI561237B (en) 2016-12-11
WO2008067871A1 (de) 2008-06-12
AU2007328052B2 (en) 2013-11-07
EP2084151A1 (de) 2009-08-05
HRP20150396T1 (hr) 2015-05-08
NZ576458A (en) 2011-12-22
US9168249B2 (en) 2015-10-27
ES2621787T3 (es) 2017-07-05
HK1140478A1 (en) 2010-10-15
MX2009004324A (es) 2009-05-12
EP2546253B1 (de) 2015-01-14
CY1114272T1 (el) 2016-08-31
JP5247712B2 (ja) 2013-07-24
PT2084151E (pt) 2013-07-18
PT2546253E (pt) 2015-05-07
SI2084151T1 (sl) 2013-10-30
AU2007328052A1 (en) 2008-06-12
GT200900095A (es) 2011-10-12
RS52924B (en) 2014-02-28
UY30663A1 (es) 2008-05-31
ES2534872T3 (es) 2015-04-29
EP2383269A3 (de) 2012-01-11
ES2421454T3 (es) 2013-09-02
RU2012134284A (ru) 2014-02-20
PH12013500578B1 (en) 2014-09-08
TWI437991B (zh) 2014-05-21
CU24056B1 (es) 2014-12-26
EP2383269B1 (de) 2017-01-18
CR10750A (es) 2009-09-16
TW201345526A (zh) 2013-11-16
JP2011006486A (ja) 2011-01-13
US20100305085A1 (en) 2010-12-02
NZ596583A (en) 2013-05-31
CN103342696A (zh) 2013-10-09
IL221928A (en) 2015-10-29
ZA200902705B (en) 2010-06-30
CU20090066A7 (es) 2011-09-21
CA2667382C (en) 2014-12-23
BRPI0717367A2 (pt) 2013-10-22
PE20120620A1 (es) 2012-05-27
CO6170359A2 (es) 2010-06-18
NO20091655L (no) 2009-06-26
PE20080895A1 (es) 2008-09-05
CR20140392A (es) 2014-09-16
PH12013500578A1 (en) 2014-09-08
CN101631785B (zh) 2013-08-21
JP2010507602A (ja) 2010-03-11
TW201630605A (zh) 2016-09-01
BRPI0717367B1 (pt) 2020-09-08
RU2009119431A (ru) 2010-12-10
TW200833330A (en) 2008-08-16
TN2009000132A1 (en) 2010-10-18
DE102006050516A1 (de) 2008-04-30
CU20110119A7 (es) 2012-01-31
RU2611012C2 (ru) 2017-02-17
HN2009000784A (es) 2012-02-27
US20120121727A1 (en) 2012-05-17
PL2084151T3 (pl) 2013-10-31
CU23743B7 (es) 2012-01-31
US8653111B2 (en) 2014-02-18
MA30914B1 (fr) 2009-11-02
EP2383269A2 (de) 2011-11-02
CA2667382A1 (en) 2008-06-12
DK2084151T3 (da) 2013-09-02
US20150148381A1 (en) 2015-05-28
BRPI0717367B8 (pt) 2021-05-25
PL2546253T3 (pl) 2015-08-31
MY169564A (en) 2019-04-22
DK2546253T3 (en) 2015-04-20
RU2469031C2 (ru) 2012-12-10
JP5300813B2 (ja) 2013-09-25
EP2546253A1 (de) 2013-01-16
US8987261B2 (en) 2015-03-24
CN101631785A (zh) 2010-01-20
KR20090074811A (ko) 2009-07-07
CN103342696B (zh) 2015-03-11
US20160229858A1 (en) 2016-08-11
KR101455879B1 (ko) 2014-11-03
HRP20130779T1 (hr) 2013-09-30
SG176421A1 (en) 2011-12-29
AR063392A1 (es) 2009-01-28
US8389520B2 (en) 2013-03-05
NO343308B1 (no) 2019-01-28
IL198289A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
HK1190153A1 (zh) 用於治療心血管和血液病的取代的二氫吡唑啉酮
HK1220839A1 (zh) 內容的分發
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
HK1114350A1 (en) An extract for preventing or treating thrombotic diseases
EP2096916A4 (en) COMPOUNDS AND METHODS FOR TREATING OSTROGEN RECEPTOR ASSOCIATED DISEASES
EP2124985A4 (en) METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
GB0624874D0 (en) Treatment
EP1932346A4 (en) DISTRIBUTION OF CONTENT
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
EP2078522A4 (en) COMPOSITION FOR THE TREATMENT OF ALLERGIES
EP2088865A4 (en) METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS
MY157996A (en) Desulfurizing coke-water salurry and process for preparation thereof
EP2057179A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF MYELOSUPPRESSION
HK1129596A1 (zh) 治療疾病的方法和配方
PL2132251T3 (pl) Kompozycja i sposób
GB0607952D0 (en) Novel treatment
GB0625208D0 (en) Composition and method
GB0604460D0 (en) Treatment
GB0600261D0 (en) Composition and method
GB0607488D0 (en) Composition and process
GB0605004D0 (en) Composition and process
GB0604315D0 (en) Composition and method
GB0607493D0 (en) Composition and process
GB0607491D0 (en) Composition and process
GB0614798D0 (en) Composition and process